180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation

Reuters

07-01

<a href="https://laohu8.com/S/ATNF">180 Life Sciences Corp</a>. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation

180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548005206"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548005206\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2548005206?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548005206","market":"nz","top_or_hot":-1,"title":"180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATNF\">180 Life Sciences Corp</a>. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-01 19:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATNF\">180 Life Sciences Corp</a>. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATNF","symbol_name":"180 Life Sciences Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL9Hwsdj:1","article_id":"2548005206","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548005206","pubTimestamp":1751370150,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATNF":"180 Life Sciences Corp","BK4139":"生物科技"},"translate_title":"180 Life Sciences Corp.通过针对纤维化疾病和神经炎症的新专利授权加强知识产权组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNF":0.9},"content_text":"180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n    \n\n        180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}